Aspect Biosystems logo

Aspect Biosystems

Developing Bioprinted Tissue Therapeutics to transform how we treat some of the most elusive diseases.

143 employees · est. 2013 · Canada

VS
Fluicell logo

Fluicell

Making tissue therapeutics possible to defeat serious disease

16 employees · est. 2012 · Sweden

Fluicell is the older company (2013 vs 2012); Aspect Biosystems is the larger of the two.

Side-by-Side Comparison

Aspect Biosystems Fluicell
Founded
2013 2012 older
Headquarters
Canada Sweden
Employees
143 larger 16
Industry
Biotechnology, Life Sciences Biotechnology, Health Care, Pharmaceutical
Funding Stage
Unknown Post Ipo Equity
Total Funding
$323.73M $4.00M
Funding Rounds
15 2
Services
Development of Bioprinted Tissue Therapeutics, Regenerative Medicine Solutions, Cutting-edge Biotech Collaborations Not tracked yet
Target Customers
Pharmaceutical Companies, Biotechnology Firms, Healthcare Providers focused on Metabolic and Endocrine Conditions, Research Institutions seeking advanced tissue therapies Not tracked yet
Taxonomy
Bioprinted Tissue Therapeutics, Cellular Medicines, Regenerative Medicine, AI-Powered Bioprinting, Hypoimmune Cell Engineering, Advanced Biomaterials, Endocrine Diseases, Metabolic Disorders, 3D Bioprinting Technology, Allogeneic Cell Therapy, Organ Function Restoration, Rare Endocrine Disorders, Diabetes Treatment, Tissue Therapeutic Platform, Partnerships In Biotech Regenerative Medicine, Drug Screening, Tissue Therapeutics, Bioprinting, Microfluidics, Biomedicine, Single-Cell Biology, Single-Cell Pharmacology, Cell Therapy, Diabetes, Precision Engineering, Transplantable Tissues, Patent-Protected R&D
Website
aspectbiosystems.com fluicell.com
Aspect Biosystems logo

About Aspect Biosystems

Aspect Biosystems is a pioneering force in the biotechnology landscape, focusing on bioprinted tissue therapeutics that promise to transform treatments for particularly elusive diseases. Their full-stack tissue therapeutic platform leverages proprietary AI-powered bioprinting technology, therapeutic...

Fluicell logo

About Fluicell

Fluicell is a Swedish biotechnology startup dedicated to revolutionizing disease treatment through innovative tissue solutions for regenerative medicine and drug screening. The company's groundbreaking Nexocyte platform, developed over two decades of disruptive R&D, introduces novel approaches to co...

Be first to know when either one moves

Funding rounds, hiring surges, leadership changes and stack switches at Aspect Biosystems and Fluicell — tracked continuously, sent the day they land.

Watch both — free

Funding, hiring, leadership and stack changes at Aspect Biosystems and Fluicell — by email.

Frequently Asked Questions

Aspect Biosystems — Developing Bioprinted Tissue Therapeutics to transform how we treat some of the most elusive diseases.. Fluicell — Making tissue therapeutics possible to defeat serious disease . Both companies operate in related markets but may differ in funding stage, team size, and product focus.
Aspect Biosystems has raised $323.73M while Fluicell has raised $4.00M.
Aspect Biosystems and Fluicell operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare Aspect Biosystems with someone else

Start typing a company name or domain.

Related Comparisons

One analytics cookie (Google Analytics). Cookie Policy